Novel dual-targeted autologous CARTs, allogeneic CARTs, and NK CARs currently in clinical trial
| Clinicaltrials.gov identifier . | Sponsor . | Phase . | Target . | Class . |
|---|---|---|---|---|
| Dual-targeted autologous CARTs | ||||
| NCT04186520 | Medical College of Wisconsin | 1/2 | CD19/CD20 | Autologous dual-target CART |
| NCT03287817 | Autolus Limited | 1/2 | CD19/CD22 | Autologous dual-target CART followed by limited duration of anti-PD-1 antibody pembrolizumab |
| Allogeneic CARTs | ||||
| NCT03939026 | Allogene Therapeutics | 1/2 | CD19 | Single-target allogeneic CART |
| NCT03398967 | Chinese PLA General Hospital | 1/2 | CD19/CD20 or CD19/CD22 | Dual-target allogeneic CART |
| NK CARs | ||||
| NCT03056339 | M. D. Anderson Cancer Center | 1/2 | CD19 | Cord blood CD19 NK CAR |
| NCT03774654 | Baylor College of Medicine | 1 | CD19 | NK CAR |
| Clinicaltrials.gov identifier . | Sponsor . | Phase . | Target . | Class . |
|---|---|---|---|---|
| Dual-targeted autologous CARTs | ||||
| NCT04186520 | Medical College of Wisconsin | 1/2 | CD19/CD20 | Autologous dual-target CART |
| NCT03287817 | Autolus Limited | 1/2 | CD19/CD22 | Autologous dual-target CART followed by limited duration of anti-PD-1 antibody pembrolizumab |
| Allogeneic CARTs | ||||
| NCT03939026 | Allogene Therapeutics | 1/2 | CD19 | Single-target allogeneic CART |
| NCT03398967 | Chinese PLA General Hospital | 1/2 | CD19/CD20 or CD19/CD22 | Dual-target allogeneic CART |
| NK CARs | ||||
| NCT03056339 | M. D. Anderson Cancer Center | 1/2 | CD19 | Cord blood CD19 NK CAR |
| NCT03774654 | Baylor College of Medicine | 1 | CD19 | NK CAR |